Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)

Number of Participants with Serious Clinical Adverse Events

Time frame: From date of enrollment through 12 weeks of study

Number of Participants with Nonerserious Clinical Adverse Events

Time frame: From date of enrollment through 12 weeks of study

Number of Participants with Serious Laboratory Adverse Events

Time frame: From date of enrollment through 12 weeks of study

Number of Participants with Nonserious Laboratory Adverse Events

Time frame: From date of enrollment through 12 weeks of study

Number of Participants Who Discontinued Due to Any Adverse Event

Time frame: From date of enrollment through 12 weeks of study

Number of Participants Who Withdrew Consent and Discontinued the Study

Time frame: From date of enrollment through 12 weeks of study

Least Squares Mean Change in Lean Body Mass

Time frame: From baseline, at 12 weeks